Teva Pharmaceuticals (TEVA) can begin selling a generic version of sexual dysfunction drug Viagra more than 2 years earlier than expected, because of a settlement with Pfizer (PFE), which makes the drug. Teva can enter the market on Dec. 11, 2017, and will pay patent royalties until expiration of the Viagra patent in '20, Pfizer said. Teva shares rose 0.3% to 39.84. Pfizer rose 0.4% to 30.14.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Teva Pharmaceuticals